Madrigal Pharmaceuticals Inc (MDGL)

NASDAQ
Currency in USD
326.79
+6.86(+2.14%)
Closed·
After Hours
305.00-21.79(-6.67%)
·
MDGL Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual Post-Market activity
Fair Value
Day's Range
313.52329.58
52 wk Range
191.18377.46
Key Statistics
Edit
Prev. Close
319.93
Open
315.76
Day's Range
313.52-329.58
52 wk Range
191.18-377.46
Volume
397.35K
Average Volume (3m)
370.08K
1-Year Change
69.03%
Book Value / Share
34.59
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MDGL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
414.07
Upside
+26.71%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year
Show more

Madrigal Pharmaceuticals Inc Company Profile

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal Pharmaceuticals Inc SWOT Analysis


Rezdiffra's Triumph
Madrigal's NASH treatment shows impressive early adoption, with prescription rates soaring to 47% and potential peak sales of $6-7.4 billion
Financial Projections
Analyst targets range from $155 to $530 per share, reflecting diverse views on Madrigal's prospects, with Q4 2024 revenue estimates around $91 million
Market Access Evolution
Explore how improvements in reimbursement processes are accelerating Rezdiffra's market penetration, with paid drug access increasing to 58%
Growth Horizons
Delve into Madrigal's potential for expanding Rezdiffra's indications and capturing a larger share of the growing NASH treatment market
Read full SWOT analysis

Compare MDGL to Peers and Sector

Metrics to compare
MDGL
Peers
Sector
Relationship
P/E Ratio
−15.5x0.0x−0.5x
PEG Ratio
1.620.000.00
Price/Book
9.6x1.2x2.6x
Price / LTM Sales
40.1x11.2x2.9x
Upside (Analyst Target)
23.9%374.8%60.5%
Fair Value Upside
Unlock16.1%8.5%Unlock

Analyst Ratings

14 Buy
1 Hold
1 Sell
Ratings:
16 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 414.07
(+26.71% Upside)

Earnings

Latest Release
Feb 26, 2025
EPS / Forecast
-2.71 / -4.48
Revenue / Forecast
103.32M / 87.70M
EPS Revisions
Last 90 days

People Also Watch

69.69
INSM
+1.06%
93.79
BMA
+1.01%
135.29
TW
+0.19%
168.06
KRYS
-0.63%

FAQ

What Is the Madrigal Pharma (MDGL) Stock Price Today?

The Madrigal Pharma stock price today is 326.79

What Stock Exchange Does Madrigal Pharma Trade On?

Madrigal Pharma is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Madrigal Pharma?

The stock symbol for Madrigal Pharma is "MDGL."

What Is the Madrigal Pharma Market Cap?

As of today, Madrigal Pharma market cap is 7.22B.

What is Madrigal Pharma Earnings Per Share?

The Madrigal Pharma EPS is -21.90.

What Is the Next Madrigal Pharma Earnings Date?

Madrigal Pharma will release its next earnings report on May 01, 2025.

From a Technical Analysis Perspective, Is MDGL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.